Dual pH/ROS‐Responsive Nanoplatform with Deep Tumor Penetration and Self‐Amplified Drug Release for Enhancing Tumor Chemotherapeutic Efficacy

Abstract

Poor deep tumor penetration and incomplete intracellular drug release remain challenges for antitumor nanomedicine application in clinical settings. Herein, a nanomedicine (RLPA‐NPs) is developed that can achieve prolonged blood circulation, deep tumor penetration, active‐targeting of cancer cells, endosome/lysosome escape, and intracellular selectivity self‐amplified drug release for effective drug delivery. The RLPA‐NPs are constructed by encapsulation of a pH‐sensitive polymer octadecylamine‐poly(aspartate‐1‐(3‐aminopropyl) imidazole) (OA‐P(Asp‐API)) and a ROS‐generation agent, β‐Lapachone (Lap), in micelles assembled by the tumor‐penetration peptide internalizing RGD (iRGD)‐modified ROS‐responsive paclitaxel (PTX)‐prodrug. iRGD could promote RLPA‐NPs penetration into deep tumor tissue, and specific targeting to cancer cells. After internalization by cancer cells through receptor‐mediated endocytosis, OA‐P(Asp‐API) can rapidly protonate in the endosome's acidic environment, resulting in RLPA‐NPs escape from the endosome through the “proton sponge effect”. At the same time, the RLPA‐NPs micelle disassembles, releasing Lap and PTX‐prodrug. Subsequently, the released Lap could generate ROS, consequently amplifying and accelerating PTX release to kill tumor cells. The in vitro and in vivo studies demonstrated that RLPA‐NPs can significantly improve the therapeutic effect compared to control groups. Therefore, RLPA‐NPs are a promising nanoplatform for overcoming multiple physiological and pathological barriers to enhance drug delivery.

Mitochondria-targeted nanoplatforms for enhanced photodynamic therapy against hypoxia tumor

“…Generally, most nanocarriers enter the tumor site via the enhanced permeability and retention (EPR) effect [ 63 ], but it’s difficult for them to penetrate deeper into the tumor tissues due to the complex tumor microenvironment (e.g., solid extracellular matrix, tight cell packing density and high interstitial flow pressure) [ 64 ], which further attenuates the therapeutic efficacy. Therefore, a variety of strategies have been reported to promote the permeation of nanocarriers including synthesis of small size or size shrinkable nanocarriers [ 65 ] and assembling nanocarriers with the tumor-penetrating cyclic peptide (e.g., iRGD) [ 64 ]. In this study, 3D tumor spheroid models were employed to assess the penetration ability of 3BP@PLGA-IR780 in vitro.…”

An Integrated Strategy for Rapid Hemostasis during Tumor Resection and Prevention of Postoperative Tumor Recurrence of Hepatocellular Carcinoma by Antibacterial Shape Memory Cryogel

“…This ability ensures that the nanoparticles are more effective at the site of the tumor with lower pH and less damage to normal tissue. [52] Besides, the whole release process lasted for nearly 5 days, which guaranteed the long-term effect of the HMME.…”

A self-amplified ROS-responsive chemodrug–inhibitor conjugate for multi-drug resistance tumor therapy

“…Among endogenous stimuli, such as low pH, enzymes, and glutathione (GSH), 14 ROS is the most promising one for comprehensive construction of responsive linkers due to its overproduction in tumor cells (10 times higher than normal cells). 15 Recently, ROS-responsive linkers, including thioether, thioketal, alkylene sulfide, selenium/tellurium, boronic ester, peroxalate ester, and polyproline, have been extensively developed. [16][17][18] Chu et al reported a ROS-responsive camptothecin (CPT) prodrug delivery system via a thioketal linker for co-delivery of photosensitizer pyropheophorbide-a (PPa) and chemodrug CPT, which could achieve on-demand CPT release.…”